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Abstract: Polycystic ovary syndrome (PCOS) affects 2%–26% of women of reproductive age 
and is often accompanied by obesity. Modest weight loss reduces health risks and ameliorates 
effects of the syndrome. Weight loss interventions are mainly of short duration and have limited 
success. A systematic review of the literature was carried out to assess the efficacy of long-term 
(12 months), nonsurgical weight loss interventions for women with PCOS. Fifteen databases 
were searched, resulting in eight papers that met the search criteria. Comparison of results and 
meta-analysis was difficult due to heterogeneity of studies. Behavioral components of interven-
tions were poorly described, and compliance was difficult to ascertain. The results suggested 
that the inclusion of a lifestyle component improves outcomes, but protocols must be clearly 
described to maintain study validity and to identify successful behavioral strategies.
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Introduction
Polycystic ovary syndrome (PCOS) involves a spectrum of endocrine and metabolic 
abnormalities, affecting an estimated 2%–26% of the women of reproductive age,1,2 
depending on the ethnicity and on the diagnostic criteria used. Clinical features of 
PCOS include hyperandrogenism, infertility, and insulin resistance. Approximately 
50% of women with PCOS are obese, with associated increased risks of diabetes, 
cardiovascular disease, and obesity-related comorbidities.3,4 These risks appear to be 
significantly reduced, and clinical features are improved by even modest weight loss 
of 5%–10%.5
Traditional nonsurgical approaches to weight loss interventions have been based 
on diet and pharmacotherapy and have shown limited success, with weight being 
regained rapidly, and with high attrition rates.6 In recent decades, the development of 
behavioral approaches to weight management, alone or in combination with diet, has 
provided evidence that inclusion of a behavioral change element can enhance weight 
loss outcomes and improve completion rates.7 Behavioral and lifestyle modification 
is important in the management of overweight and obesity, as a chronic condition, 
in the longer term.8 A multidisciplinary approach is essential to prevent weight gain 
and to achieve and sustain weight loss, particularly when fertility is impaired.9 This 
requires consideration of psychosocial and practical factors in addition to physiological 
influences.10 However, multidisciplinary interventions are resource intensive and are International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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commonly delivered for short periods only. Further, 
  counseling and lifestyle strategies, and the protocols for 
delivery are often poorly described.11
There is little evidence that short-term interventions 
are effective, in either health or economic terms over 
longer   periods following completion. It is important to 
evaluate long-term ($12 months), nonsurgical weight 
loss   interventions, with and without behavioral or lifestyle 
counseling and support, and to identify effective counsel-
ing strategies for the development of standard counseling 
protocols for comparison.
The aim of this study was to systematically review the 
efficacy of long-term (12 months), nonsurgical weight loss 
interventions and to identify specific behavioral weight loss 
strategies for obese women with PCOS.
Materials and methods
A systematic review was undertaken to evaluate the success 
of long-term ($12 months), nonsurgical weight loss inter-
ventions for women with PCOS and to identify counseling 
strategies used in these interventions. The protocol for this 
review was based on the methods recommended by the 
Cochrane Collaboration.12
A comprehensive search was performed using 15 online 
databases: AMED, ASLIB, ASSIAnet, Blackwell Synergy, 
CAB abstracts, CINHAL, Cochrane Library, IngentaCon-
nect, MetaPress, MEDLINE, Oxford University Press, 
Science Citation Index, Social Sciences Citation Index, 
ScienceDirect, SAGE Journals Online. Articles, in Eng-
lish, published between January 1998 and June 2008 were 
reviewed. Inclusion criteria were all prospective long-term 
(12 months) studies of women with a diagnosis of PCOS and 
mean body mass index (BMI) $28 kg/m2, where weight loss 
was a primary or secondary outcome measure. Participant 
criteria were restricted to those conducted in adult popula-
tions with a minimum age .18 years and no ethnic groups 
were excluded. The review included randomized controlled 
trials and cohort studies.
The initial search was conducted by one researcher, who 
performed a search of databases to identify relevant articles 
from titles and abstracts. Those articles that appeared to meet 
search criteria were retrieved and examined as full copies to 
determine which ones met standardized eligibility criteria. 
Search terms included weight loss, obesity, obes*,   polycystic 
ovar* syndrome according to specific requirements for 
advanced search in each database. Wildcards and Boolean 
operators were used to ensure inclusion of various forms for 
each search term. The publication Human   Reproduction, 
which yielded two eligible studies, was hand-searched   during 
the period January 2003–June 2008, and the reference lists 
of all included studies were searched for further relevant 
articles.
Two researchers independently assessed full copies 
of the selected studies to establish methodological qual-
ity using a standardized form. Agreement was ensured 
by discussion. Neither researcher was blinded to author, 
publication, or institution. Data were abstracted by one 
researcher using a standardized form and independently 
checked for accuracy by the second researcher. Data were 
entered into a software package, Review Manager 4.2.2, 
for analysis.
The review evaluated interventions including diet, 
pharmacotherapy, and behavioral or lifestyle intervention in 
which weight loss was a primary or a secondary outcome. 
The included interventions were as follows:
•  Pioglitazone + metformin in women with PCOS nonre-
sponsive to metformin + diet13
•  Spironolactone with and without diet14
•  Metformin + diet vs diet15
•  Metformin with diet16
•  Rosiglitazone + oral contraceptive17
•  Flutamide, metformin, and combination therapy + diet18
•  Diet + exercise19
•  Metformin vs lifestyle + placebo vs metformin + lifestyle 
vs placebo20
Out of 71 studies initially identified, only eight met the 
  inclusion criteria for this review. Reasons for the exclusion 
of these studies are detailed in Table 1.
Studies reviewed included three randomized controlled 
trials (RCTs), with the remaining five being prospective 
cohort studies. The RCTs are described in Table 2.
One RCT was of 48 weeks duration, and a further study 
included patients who were followed up for only 40 weeks.
Of the five cohort studies, one lasted for 4 years, but 
only data obtained within 1 year is reported here; three were 
carried out by the same principal author. In only three studies, 
weight loss was the primary outcome. Details of cohort 
studies are described in Table 3.
Table 1 excluded studies
Reasons for exclusion Number
Study duration ,40 wk 34
Minimum age ,18 y 7
Review articles 22
Note: This table indicates the reasons for excluding published studies that were 
initially identified in a systematic review of the literature.International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Table 2 Randomized controlled trials
Principal 
author
Study design Participants Intervention
Hoeger20 Prospective randomized trial  
over 48 wk
38 obese women with PCOS, 
whose insulin failed to normalize 
after 4 mo on the diet
Metformin (n = 9) vs 
Lifestyle modification + placebo (n = 11) vs 
Metformin + lifestyle modification (n = 9) vs 
Placebo (n = 9)
Lemay17 Prospective randomized cross-over trial  
over 12 mo following 4 mo diet
28 overweight or obese women 
with PCOS (23 completers)
Group A: rosiglitazone + diet for 6 mo (n = 15) 
Group B: oral contraceptive 
(ee/CPA) + diet for 6 mo (n = 13) 
At 6 mo, groups A and B commenced 
rosiglitazone + ee/CPA for further 6 mo
Gambineri18 Prospective randomized 
controlled trial over 12 mo
80 overweight or obese women 
with PCOS (76 completers)
Diet + placebo (n = 19) vs 
Diet + metformin (n = 20) vs 
Diet + flutamide (n = 17) vs 
Diet + metformin + flutamide (n = 20)
Note: This table provides intervention details for the three randomized controlled trials that were included in this review.
Abbreviation: PCOS, polycystic ovary syndrome.
Table 3 Cohort studies
Principal 
author
Study design Participants Intervention
Glueck16 Prospective cohort study  23 obese women with PCOS and idiopathic 
intracranial hypertension
Metformin + hypocaloric diet (n = 20) 
Hypocaloric diet (n = 3)
Zulian14 Prospective cohort study 25 lean and overweight women with PCOS Group A (BMI , 25) received spironolactone 
12 mo (n = 13) 
Group B (BMI . 25) received spironolactone 
12 mo + dietary restriction (n = 12) 
Completers: 
Group A (n = 5) 
Group B (n = 7)
Glueck13 Prospective cohort study 39 obese women with PCOS After 12 mo of metformin: group A 
(nonresponsive to metformin) received 
pioglitazone in addition for 10 mo (n = 13) 
Group B (responsive to metformin) on 
metformin (n = 26)
Glueck15 Prospective cohort study 89 obese women with PCOS, treated with 
metformin + diet targeted to entry weight
Metformin + annual dietary instruction (n = 89) 
Dietary adherence was not assessed
Crosignani19 Prospective cohort study 33 obese women with PCOS and chronic 
anovulation
1200 kcal/d diet + physical exercise (n = 33) 
Completers (n = 11)
Note: This table provides intervention details for the five cohort studies that were included in this review.
Abbreviations: PCOS, polycystic ovary syndrome; BMI, body mass index.
Results
Results for all studies are summarized in Table 4. It was not 
possible to perform a meaningful meta-analysis of weight loss 
outcomes due to the heterogeneous nature of these studies. 
Of the three RCTs, only one study by Hoeger et al20 included 
a lifestyle counseling component consisting of prescribed 
diet and exercise plan with initial (24-week duration) weekly 
support, education and monitoring, and subsequent biweekly 
monitoring. In this study, significant weight loss was seen 
in groups receiving lifestyle education and support, with 
and without metformin (−8.9 ± 2.9 kg and −6.8 ± 3.8 kg, 
respectively), and in the group receiving only metformin 
(−6.5 ± 3.7 kg), but not in the placebo group (−0.2 ± 0.8 kg). 
Thus, intensive lifestyle counseling enhanced weight loss, 
with or without metformin. Of the 38 participants (metformin 
group 4, lifestyle + placebo group 5, lifestyle + metformin 
group 4, and placebo group 2), 13 failed to complete the 
intervention, resulting in an overall attrition rate of 39.5%.
In a RCT by Gambineri et al,18 which compared 
diet +   flutamide and metformin alone and combined, the diet + pla-
cebo group achieved a weight loss comparable to Hoeger’s20 
lifestyle + placebo group, with −5 ± 16 kg vs −6.8 ± 3.8 kg, International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Table 4 Trials of nonsurgical, long-term weight loss interventions and their impact on weight change
Principal 
author
Intervention Group A  
results
Group B 
results
Group C  
results
Group D  
results
Hoeger20 Metformin (n = 9) 
Lifestyle change + placebo (n = 11) 
Metformin + lifestyle change (n = 9) 
Placebo (n = 9)
M: −6.5% weight LC + Pl:  
−6.8% weight
LC + M:  
−8.9% weight
Pl:  
−0.2% weight
Lemay17 Group A: rosiglitazone + diet for  
6 mo (n = 15) 
Group B: oral contraceptive 
(ee/CPA) + diet for 6 mo (n = 13) 
At 6 mo, groups A and B commenced 
rosiglitazone and ee/CPA
No significant  
weight change
No significant  
weight change
Gambineri18 Diet + placebo (n = 20) 
Diet + metformin (n = 20) 
Diet + flutamide (n = 20) 
Diet + metformin + flutamide (n = 20)
D + Pl: −5 ± 16 kg D + M:  
−4 ± 13 kg
D + F: 
 −9 ± 9 kg
D + M + F:  
−10 ± 14 kg
Glueck16 Metformin + diet (n = 20) 
Diet (n = 3)
M + D: −7.7% weight D: −3.3% weight
Zulian14 Group A (BMI , 25): spironolactone for 
12 mo (n = 5) 
Group B (BMI . 25): 
spironolactone + diet for 12 mo (n = 7)
No weight loss Mean BMI:  
−2 ± 4.7 kg
Glueck13 Groups A and B: metformin for 12 mo 
Group A: pioglitazone for 10 mo 
(n = 13) 
Group B: metformin for 10 mo (n = 26)
No weight loss Median:  
−6 kg weight
Glueck15 Metformin + dietary advice (n = 89) Mean: (8.9% weight
Crosignani19 Diet + physical exercise (n = 33) 76% (n = 25):  
$−5% weight 
33% (n = 11):  
$−10% weight
Note: This table displays the results for each study included in the systematic review. The first three articles presented here are randomized controlled trials and the latter 
five are prospective cohort studies.
Abbreviations: M, metformin; LC, lifestyle change; Pl, placebo; D, diet; F, flutamide; BMI, body mass index.
but with a large standard deviation. The diet + metformin 
group achieved ,50% of the weight loss found in Hoeger’s 
comparable group (−4 ± 13 kg vs −8.9 ± 2.9 kg). However, 
Gambineri et al’s diet + flutamide group achieved a weight loss 
of −9 ± 9 kg, and the diet + flutamide + metformin achieved 
most weight loss, −10 ± 14 kg, but with a wide range of indi-
vidual results. Reported attrition was only 5% in this study 
and, in part, due to pregnancy.
In the third RCT with cross-over design, Lemay et al17 
found no significant weight loss in the groups that received 
rosiglitazone, oral contraceptive (EE/CPA), and a combi-
nation of the two drugs, and these data were not reported 
in the article. Weight loss was not a principal aim of this 
study. In the group that initially commenced rosiglita-
zone + diet, 33.4% of participants dropped out, whereas 
in the group that initially commenced EE/CPA + diet, the 
attrition rate was 46.2%. In the remaining studies, dropout 
data were not provided. It was not possible to compare 
weight loss results between the RCTs and cohort studies 
as the remaining studies reported only percentage change 
in either weight or BMI, with insufficient data to make 
relevant calculations.
In Crosignani et al’s19 cohort study of diet and physi-
cal exercise, it was unclear when weight loss of 5% and 
10% was achieved either as a group mean or as individual 
results; therefore, it can be assumed that some participants 
were not followed up for a full 40-week period. However, 
this diet + exercise intervention resulted in 76% (n = 25) 
women losing $5% weight, and 33% (n = 11) women los-
ing 10% weight within the 40-week period. There was sparse 
description of intervention strategies. A 1200-kcal diet was 
prescribed, and aerobic exercise such as swimming or aero-
bics was recommended, but without prescribed duration or 
frequency. Compliance was ascertained only by weight loss. 
This was an unobtrusive intervention, therefore, with progress 
monitoring every 6–8 weeks.International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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The results of Crosignani et al study compared favorably 
with Glueck’s15 cohort study of sustainability of weight loss 
on metformin + diet, in which at 12 months, weight loss 
of −8.1% was found in 89 participants who completed the 
intervention. This was also a nonintensive study, in which par-
ticipants were initially provided with dietary instruction and 
received annual dietary follow-up. Progress was monitored 
at 2-month intervals throughout the study. Sustainability of 
weight loss was a primary aim.
In another cohort study by Glueck et al13 on the effects 
of metformin + diet vs metformin + diet + pioglitazone in 
metformin nonresponders, pioglitazone had little effect 
on weight loss. Non metformin-responsive participants 
showed no weight change even with the addition of pio-
glitazone, whereas in the metformin-responsive group, 
significant weight loss (median 6 kg) was achieved with 
metformin + diet. Progress was monitored at 2-month inter-
vals, but dietary support was not described.
Glueck et al’s16 third cohort study that sought to improve 
clinical signs and symptoms of idiopathic intracranial hyper-
tension (IIH) in a group of 20 women with PCOS involved 
the use of diet and metformin. A weight change of −7.7% was 
achieved within 10 months in women receiving a 1500-kcal/d 
high-protein diet plus metformin therapy. There was no 
description of weight monitoring or support for this group. 
In the three studies reported by Glueck et al, only data from 
participants who completed the intervention were included.
In Zulian et al’s14 comparison of spironolactone vs 
spironolactone + lifestyle modification, only participants in 
the latter group lost significant weight. Only 12 participants 
were overweight or obese and were assigned as a cohort to one 
of the following two groups: those who received spironolac-
tone only (mean BMI, 28.6 ± 4.7 kg/m2; n = 5) and those 
who received lifestyle modification + spironolactone (mean 
BMI, 30.3 ± 3.5 kg/m2; n = 7). Weight measurements were 
not given. In the former group, final BMI was 29 ± 5.4 kg/m2, 
and in the latter group, final BMI was 26.3 ± 3.4 kg/m2, 
P , 0.05. Lifestyle modification was described only as 
food restriction, 1400 kcal/d, and there was no description 
of monitoring or support.
Discussion
Two studies, by Gambineri et al,18 and Hoeger et al,20 reported 
similar results for their diet and lifestyle + placebo arms; 
however, Gambineri et al’s18 results indicated a wide range of 
individual results. Gambineri et al’s18 diet + metformin group 
achieved ,50% of the weight loss found in Hoeger et al’s20 
comparable group, which perhaps reflected the benefits 
of intensive lifestyle support in the early weeks, with less 
intensive early support for participants potentially affecting 
individual motivation.
Reported dropout in Gambineri et al’s18 study was only 
5%, and possible reasons for this unusually low attrition rate 
were not discussed by the authors, but may be attributable 
to a lesser emphasis on weight loss and thus less restrictive 
dietary prescription and monitoring. The inclusion of a 
qualitative investigative component in studies of this type, to 
ascertain participant experiences and perceptions of weight 
loss interventions, could provide insight into the underlying 
causes for attrition and ways of enhancing the patient experi-
ence to improve compliance.
Lemay et al’s17 study of rosiglitazone + diet vs oral 
contraceptive (EE/CPA) + diet was not primarily aimed 
at weight loss, and this lack of emphasis may explain the 
lack of weight change. However, there was a notable differ-
ence in attrition rates in each arm of this study with the EE/
CPA group having a higher noncompletion rate than in the 
rosiglitazone arm. Possible reasons for this difference were 
not discussed, but may reflect lesser participant satisfaction 
with EE/CPA during the first stage of the study when attri-
tion rate is traditionally higher and benefits have yet to be 
seen. Alternatively, EE/CPA might cause more unpleasant 
side effects, affecting compliance unfavorably in the initial 
stages. Again, an investigation of participants’ experiences 
and perceptions of this intervention may have provided useful 
insight into patients’ failure to complete.
All but two studies used the ESHRE-ASRM (2003) con-
sensus criteria for diagnosis of PCOS, which stipulates the 
presence of at least two of three of the following:
•  Presence of clinical or biochemical hyperandrogenism
•  Ovarian dysfunction – oligo-anovulation or polycystic 
ovaries
•  Exclusion of other etiologies related to hyperandrogenism 
or infertility
However, Hoeger et al20 used the National Institutes of 
Health 1990 consensus criteria of chronic anovulation and 
clinical or biochemical signs of hyperandrogenism, with 
exclusion of other etiologies, whereas Crosignani et al19 
used the criteria of chronic anovulation and polycystic 
ovaries, with exclusion of other etiologies. As discussed by 
March et al,2 this may have led to the inclusion of different 
phenotypic groups in the reviewed studies. It is difficult to 
assess whether the use of differing diagnostic criteria for 
PCOS affected the results reviewed here. However, the use 
of different diagnostic criteria limits the interpretation of 
study results.International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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The results of this review, particularly for the study by 
Hoeger et al,20 support the view expressed by Brown et al7 
that ongoing support and education is an important compo-
nent of a weight loss intervention, enhancing the effects of 
drug therapies. Norman et al9 argue that weight management 
should be a first-line treatment option for overweight or obese 
women seeking fertility, and this should comprise a range of 
strategies including diet, exercise, and behavior modification. 
However, in this review, the lack of description of support 
strategies, lifestyle counseling, and educational focus renders 
comparisons difficult. Furthermore, Dombrowski et al11 sug-
gests that failure to detail the intervention protocol and to 
ensure intervention delivery according to protocol renders the 
investigation invalid. This review highlights the importance of 
a clear, detailed description of intervention protocols, includ-
ing the use of specific counseling, behavioral and educational 
strategies, and the need to use consistent diagnostic criteria.
Of the drugs reviewed, in one study, the antiandrogen 
flutamide appeared more successful in supporting weight 
loss, although historically, metformin appears to be the more 
popular treatment choice, and further comparison of the 
relative efficacy of these drugs in regulating weight might 
be helpful. However, it must be noted that neither metformin 
nor flutamide, per se, is a weight loss drug. Spironolactone 
and pioglitazone were not helpful in supporting weight loss 
in this patient group in these single studies. This highlights 
a need for further investigation of the role and efficacy of 
drugs used in weight loss interventions aimed specifically 
at women with PCOS.
Comparison of study results within this review is difficult 
due to heterogeneity of approaches to weight loss, differences 
in diagnostic tools, and poor description of lifestyle com-
ponents of such interventions. This review fails to provide 
supportive evidence for specific lifestyle and behavioral 
strategies due to poor description of these and how they were 
used. Furthermore, only 2 RCTs had placebo controls and 
5 studies compared treatment regimens with no control group. 
Two studies offered all participants the same intervention, 
although one had a cross-over design.
It can be concluded that there is a poor evidence base 
for current nonsurgical approaches to weight loss in obese 
women with PCOS due to poor description of interventions 
and lack of comparable weight loss data from longer-term 
(.12 months) studies. The relatively poor completion and 
success rates suggest a need for evidence-based practices 
that better engage obese participants in the process of long-
term behavior change and to empower them to manage their 
weight successfully in the longer term.
The fidelity of adherence to behavioral and lifestyle 
change protocols by weight management staff remains 
unclear. Approaches to weight loss interventions remain vari-
able, and intervention strategies have been poorly described 
in the literature. Reported interventions were based on an 
expert-led, directive medical model of obesity, which may 
fail to address the emotional aspects of obesity or to fully 
utilize individual agency for behavioral change for effective, 
long-term self-management of weight.
In view of the chronic nature of obesity, effective, long-
term self-management of weight must be the key to reducing 
costs, in health and in social and economic terms of this bur-
geoning pandemic. It is difficult to ascertain from the existing 
literature which behavioral change strategies are most success-
ful and ultimately offer best value per unit resource. However, 
this review highlights the lack of nonpharmacological-based 
trials to evaluate treatment for obese women with PCOS. 
There is a need for further investigation and comparison of 
weight loss interventions based on behavioral change, with 
and without concurrent drug therapy. Future studies of weight 
loss interventions should adopt a standardized diagnostic 
approach, with careful reporting of weight change data, and 
provision of detailed descriptions of lifestyle intervention 
protocols and behavioral change strategies.
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